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Abstract
Background: The objective of this study was to assess the benefit of temporary combination antiretroviral therapy (cART)
during primary HIV infection (PHI).
Methods and Findings: Adult patients with laboratory evidence of PHI were recruited in 13 HIV treatment centers in the
Netherlands and randomly assigned to receive no treatment or 24 or 60 wk of cART (allocation in a 1:1:1 ratio); if therapy
was clinically indicated, participants were randomized over the two treatment arms (allocation in a 1:1 ratio). Primary end
points were (1) viral set point, defined as the plasma viral load 36 wk after randomization in the no treatment arm and
36 wk after treatment interruption in the treatment arms, and (2) the total time that patients were off therapy, defined as
the time between randomization and start of cART in the no treatment arm, and the time between treatment interruption
and restart of cART in the treatment arms. cART was (re)started in case of confirmed CD4 cell count ,350 cells/mm3 or
symptomatic HIV disease. In total, 173 participants were randomized. The modified intention-to-treat analysis comprised
168 patients: 115 were randomized over the three study arms, and 53 randomized over the two treatment arms. Of the 115
patients randomized over the three study arms, mean viral set point was 4.8 (standard deviation 0.6) log10 copies/ml in the
no treatment arm, and 4.0 (1.0) and 4.3 (0.9) log10 copies/ml in the 24- and 60-wk treatment arms (between groups:
p,0.001). The median total time off therapy in the no treatment arm was 0.7 (95% CI 0.0–1.8) y compared to 3.0 (1.9–4.2)
and 1.8 (0.5–3.0) y in the 24- and 60-wk treatment arms (log rank test, p,0.001). In the adjusted Cox analysis, both 24 wk
(hazard ratio 0.42 [95% CI 0.25–0.73]) and 60 wk of early treatment (hazard ratio 0.55 [0.32–0.95]) were associated with time
to (re)start of cART.
Conclusions: In this trial, temporary cART during PHI was found to transiently lower the viral set point and defer the restart
of cART during chronic HIV infection.
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Introduction
The optimal management of primary HIV infection (PHI) and
the possible impact of temporary combination antiretroviral
therapy (cART) on clinical outcome are controversial [1,2].
Reported benefits of temporary early cART from previous
observational studies include lowering of the viral set point [3–
5], a slower decline of CD4 T cells [6], partial normalization of
CD4 T cell subsets [7], preservation of HIV-specific immune
responses [8–10], and limitation of viral reservoirs established
during the first few weeks after transmission [11]. However, other
cohort studies have not confirmed an effect on viral set point [12–
15] or have reported a similar or faster decline of CD4 T cells in
patients treated during PHI [16,17].
From a clinical perspective, an important question is whether
patients who are treated during PHI remain off treatment longer
than patients in whom treatment is deferred until indicated based
on their CD4 cell count or clinical condition. A randomized
controlled trial of 6 mo of zidovudine monotherapy in patients
with PHI reported a reduction of minor opportunistic infections
during the first year of follow-up [18]. Results of two randomized
controlled trials in the cART era suggested a clinical benefit of
temporary treatment during PHI [19,20]. Preliminary results of
the SPARTAC trial, which compared 12 and 48 wk of cART with
no therapy during PHI, reported a modest delay in disease
progression after 48 wk of cART [19]. The SETPOINT study
aimed to compare 36 wk of cART with deferred therapy in early
HIV infection, but was prematurely stopped in June 2009 by the
Data Safety and Monitoring Board, because of a higher rate of
disease progression in the untreated arm [20].
We conducted the Primo-SHM trial, in which patients with PHI
were randomized between no treatment and 24 and 60 wk of early
cART. The aim of the study was to assess the clinical benefit of
temporary cART initiated during PHI, measured by the time that
patients could remain off therapy until subsequent (re)start of
cART was indicated based on current treatment guidelines, and to
assess the optimal duration of such early treatment.
Methods
Study Population
Inclusion criteria were age over 18 y and laboratory evidence of
PHI infection, defined as a negative or indeterminate Western blot
in combination with detectable plasma HIV-1 RNA (Fiebig stage
I–IV) or, in case of a positive Western blot, a documented negative
HIV screening test in the previous 180 d (Fiebig stage V–VI [21]).
Women were counseled to use adequate contraception; pregnant
and breast-feeding women were excluded. The study was
approved by the Medical Ethics Committee of each participating
site, and written informed consent was obtained from all
participants. The study protocol and the CONSORT checklist
are provided as Text S1 and Text S2, respectively.
Design
The Primo-SHM trial was a multicenter, open-label random-
ized controlled trial comparing temporary early cART (24 or
60 wk) with no treatment. Patients were recruited in 13 HIV
treatment centers in the Netherlands. Participants were randomly
assigned to receive no treatment or 24 or 60 wk of cART (three-
way randomization). In cases where treatment was clinically
indicated based on severe clinical symptoms (e.g., HIV-related
meningitis) or the patient insisted on starting early cART,
participants were randomized over the 24- and 60-wk treatment
arms only (two-way randomization).
The study was designed to evaluate (1) the effect of temporary
treatment during PHI on the viral set point, defined as the plasma
viral load (pVL) at 36 wk after randomization in the no treatment
arm and at 36 wk after treatment interruption (TI) in the
treatment arms, and (2) the total time that patients were off
therapy after randomization (treatment-free period). The analyses
of the viral set point and the total time off therapy were restricted
to patients who were randomized over all three study arms. A
second comparison evaluated the optimal duration of early cART
by comparing all patients who were treated with 24 or 60 wk of
cART, including patients from both the three- and two-way
randomization.
Recruitment started 1 May 2003 and continued until 31 March
2010. The present analysis includes follow-up data until 14
September 2011.
Randomization
Patients were allocated to one of the three study arms using a
computerized minimization algorithm with stratification for the
stage of PHI (Fiebig stage I–II, III–IV, or V–VI). The Dutch HIV
Monitoring Foundation performed the randomization procedure,
had no interaction with study participants, and was responsible for
data management. Randomization results were sent by fax to the
clinical investigators, who were unaware of the allocation
procedure.
Procedures
Early cART consisted of a triple-class regimen of zidovudine/
lamivudine (300/150 mg bid), efavirenz (600 mg qd), and
lopinavir/ritonavir capsules (533/133 mg bid). The last was
discontinued when the pVL dropped below 50 copies/ml.
Changes to this regimen were allowed in case of transmitted drug
resistance or if one of the drugs was contraindicated or not
tolerated. After 28 January 2008, zidovudine/lamivudine was
replaced by tenofovir/emtricitabine (245/200 mg qd), according
to the Dutch standards of care, and lopinavir/ritonavir tablets
(600/150 mg bid) replaced the capsules. Patients on early cART
were required to reach viral suppression below 50 copies/ml in
plasma before interrupting therapy.
Baseline evaluations included a medical history including the
presence of symptoms compatible with an acute retroviral
syndrome, a physical examination, and collection of blood for
routine hematology and chemistry, CD4 and CD8 cell counts,
pVL, hepatitis B and C serology, and storage of peripheral blood
mononuclear cells. All study sites used a sensitive HIV RNA assay
with comparable accuracy and a lower limit of detection of 40 or
50 copies/ml [22]. The assays that were used were Amplicor HIV-
1 Monitor ultrasensitive RNA assay (Roche), Amplicor HIV-1
Monitor, Cobas Amplicor, Cobas TaqMan HIV-1 (Roche
Diagnostics), m2000rt HIV RNA (Abbott), NucliSens EasyQ
(bioMe´rieux), Quantiplex bDNA 3.0 (Chiron), and Versant HIV
RNA 3.0 Assay (Siemens Healthcare Diagnostics). Standard HIV-
1 genotyping and subtyping were performed at most participating
sites. Drug-resistance mutations were identified according to the
World Health Organization Surveillance Drug-Resistance Muta-
tion list [23], using the calibrated population resistance tool of the
Stanford University HIV Drug Resistance Database (http://
hivdb.stanford.edu/) [24]. In patients recruited at the Academic
Medical Center of the University of Amsterdam, additional viral
and host genetic analyses were performed: the presence of
CXCR4-using viruses at baseline, CCR5 D32 genotyping, and
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human leucocyte antigen (HLA) typing. CXCR4 coreceptor usage
was determined using the MT-2 assay [25].
Randomization was performed at week 0, and patients
randomized to receive cART started treatment. Patients were
scheduled for follow-up visits at weeks 2, 4, 8, and 12, and every
12 wk thereafter for the duration of the study. Additional visits
were scheduled at weeks 4, 8, and 12 following TI. During each
follow-up visit, blood was collected for routine hematology and
chemistry, CD4 and CD8 cell counts, pVL, and storage of
peripheral blood mononuclear cells.
Primary End Points
The primary efficacy end points were (1) the viral set point,
defined as pVL at 36 wk after randomization in the no treatment
arm and pVL at 36 wk after TI in the treatment arms, and (2) the
total time that patients were off therapy, defined as the time
between randomization and start of cART in the no treatment
arm, and as the time between TI and restart of cART in the
treatment arms. We chose the viral set point as the pVL at 36 wk
to allow for stabilization of the pVL in untreated and treated
patients [3,5,13,14] and to minimize drop out due to rapid disease
progression. (Re)start of cART was defined as the moment when
the criteria for (re)start of cART were met—a CD4 cell count
below 350 cells/mm3 on two consecutive occasions, severe
constitutional symptoms, or the occurrence of an AIDS-defining
event [26]—or if the physician or patient insisted on (re)initiating
cART, whichever occurred first. We also explored the time to
(re)start of cART with a CD4 cell count threshold of 500 cells/
mm3 or less on two consecutive occasions [27,28]. In the no
treatment arm, the CD4 count criterion was not applied during
the first 12 wk after randomization, because of the transiently low
CD4 cell counts often observed during PHI.
Statistical Analysis
At the time the protocol was developed in 2002, insufficient data
were available to make a reliable estimation of the sample size
needed to detect a clinically significant difference between the
study arms in viral set point and time to (re)start of cART. An
estimated number of 30 patients were expected to be enrolled
annually, and in the protocol amendment of 28 January 2008, the
end of study inclusion was set at March 2010, when we expected
to have enrolled approximately 200 patients.
As defined in the study protocol, we conducted a modified
intention-to-treat (mITT) analysis: participants who withdrew
consent because they insisted on starting early cART while
randomized to the no treatment arm or those who declined
therapy after being randomized to one of the treatment arms were
excluded from the analysis. In a standard intention-to-treat
analysis, patients who are randomized to the no treatment arm
but insist on starting treatment immediately have 0 d of survival
since they reach the study end point immediately at initiation of
treatment, and patients who are randomized to one of the
treatment arms but refuse to start early treatment reach the study
end point only at the moment they eventually start cART. This
results in a strong and unnecessary bias in favor of the treatment
arms. Therefore, we report the mITT analysis, in which patients
who did not start with the allocated treatment plan were excluded.
Participants who were lost to follow-up while still on early
cART were not included in the analyses. Patients who discontin-
ued early cART before completing the scheduled period of 24 or
60 wk remained in the mITT analysis. Participants who did not
discontinue early cART at the scheduled TI date or were lost to
follow-up after randomization/TI were considered having reached
the (re)start end point. Per protocol analyses were performed
excluding patients who discontinued cART earlier than planned
and patients who did not discontinue cART at the scheduled TI
date but instead elected to continue cART for reasons other than a
low CD4 count or symptomatic disease. Patients who had not yet
(re)started cART were censored at the last follow-up visit.
Reported results concern data from the three-way randomized
patients unless stated otherwise. Viral set point and the CD4 cell
count measured at viral set point were compared using one-way
ANOVA. The evolution of pVL and CD4+ T cell count following
randomization/TI in the no treatment/treatment arms were
analyzed using linear mixed models incorporating repeated
measurements. Both the pVL and CD4 evolution showed a tri-
phasic pattern with distinct slopes from week 0 to 8, week 8 to 36,
and week 36 to 144. The total time off therapy for the no
treatment versus the treatment arms was analyzed using the mITT
population of the three-way randomized patients. For the second
comparison, which evaluated the optimal duration of early cART,
we combined the data of all treated patients, including those
participants who were randomized over the two treatment arms.
In both analyses, the total time off therapy was compared across
the study arms using Kaplan-Meier plots and log rank tests.
We fitted a series of multivariable Cox regression models of time
to (re)start of cART using the mITT population and the per
protocol population of the three-way randomized patients
separately and of the three- and two-way randomized patients
combined. Because the sample size of our study was relatively
small, the study arms might by chance be imbalanced with regard
to certain prognostic factors. To reduce potential bias, we
weighted all Cox regression analyses using propensity score
weights [29]. Weights were calculated separately for each analysis
using multivariable logistic regression with a generalized logit link
function. The models included potential confounders that from the
literature are known to influence HIV disease progression and that
were measured at baseline: gender, age, country of origin, HIV-
transmission risk category, baseline CD4 cell count, stage of PHI,
symptomatic during PHI, resistance profile, HIV-1 subtype B/
non-B, protective HLA alleles, X4/R5-tropism, heterozygosity for
CCR5 D32 deletions, and viral hepatitis. All models using data
from the three- and two-way randomized patients combined were
additionally adjusted for the randomization scheme of each
patient. The proportional hazards assumption was checked.
We hypothesized that the proposed mechanism by which early
cART may result in a clinical benefit was by lowering of the viral
set point and/or by increasing the CD4 cell count during the
treatment period. Therefore, we also fitted Cox models that
included the viral set point at 36 wk after randomization/TI in the
no treatment/treatment arms and the CD4 cell count measured at
viral set point. To further explore which factors might be
associated with time to (re)start of cART, other than temporary
early cART, viral set point, and CD4 cell count at viral set point,
we performed a final sub-group analysis for which we selected all
patients who had been randomized to one of the early treatment
arms and fitted a multivariable Cox model using a stepwise
selection process using all aforementioned variables. Data were
analyzed using SPSS version 18.0 (SPSS) and SAS version 9.1.3
(SAS Institute). All reported p-values were two-sided and
considered statistically significant when less than 0.05.
Results
Patient Characteristics
The patient enrollment is summarized in Figure 1: 238 eligible
PHI patients were screened, of whom 173 were enrolled. Four
participants withdrew consent and one patient developed an acute
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hepatitis B infection and was withdrawn from the study by the
treating physician immediately following randomization. These
five patients were excluded from all analyses. The mITT
population consisted of 168 patients: 115 were randomized over
the three study arms, and 53 were randomized over the two
treatment arms only. Four patients were lost to follow-up while on
early cART and were not included in the survival analyses. Of the
three-way randomized patients, five interrupted cART earlier
than planned, and three did not interrupt cART as planned, of
whom two had a low CD4 cell count at the scheduled TI date. Of
the two-way randomized participants, one interrupted cART
earlier than planned, and five participants did not discontinue
early cART as planned, of whom one had a low CD4 cell count at
the scheduled TI date. These 14 patients remained, according to
the protocol, in the analysis (Figure 1). Participants were followed
for a period between 3 and 400 wk, with a median follow-up of
100 (interquartile range [IQR] 60–160) wk.
Demographic and baseline characteristics of the three-way
randomized patients are summarized in Table 1. Most patients
were men who have sex with men, had a negative or
indeterminate Western blot (Fiebig stage I–IV), and were
symptomatic during PHI. The mean baseline CD4 cell count
was 458 (standard deviation [SD] 183) cells/mm3 in the no
treatment arm, and 584 (230) cells/mm3 and 483 (241) cells/mm3
in the 24- and 60-wk treatment arms. The multivariable Cox
regression analyses were adjusted for this baseline difference. Nine
of 99 patients (9%) for whom HIV genotyping was available
harbored transmitted drug-resistance mutations: in eight patients a
single mutation in reverse transcriptase or protease was present,
and one patient harbored a mutation in both reverse transcriptase
Figure 1. CONSORT flow diagram. HBV, hepatitis B virus; LTFU, loss to follow-up.
doi:10.1371/journal.pmed.1001196.g001
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and protease. All participants were treated with at least three
active drugs during early cART. The presence of CXCR4-using
viruses at baseline, CCR5 D32 heterozygosity, and HLA B27 or
B57 were equally distributed between the three study arms. One
untreated patient had a chronic hepatitis B infection, and none
had hepatitis C infection. Patients on early cART had a median
delay of 2 (IQR 0–6) d between randomization and start of early
cART. The study drugs were well tolerated and caused no serious
adverse events.
No differences in baseline characteristics were seen between the
three- and two-way randomized treated patients, with the
exception of the nucleoside backbone (zidovudine/lamivudine
versus tenofovir/emtricitabine) used during early cART (Table
S1).
Treatment Interruption, Viral Set Point, and CD4 Cell
Count Changes
Of the three-way randomized patients, 66/76 treated partici-
pants (87%) had a pVL below 50 copies/ml at the time of TI. Five
patients interrupted early cART on the scheduled TI date even
though their pVL was not below 50 copies/ml (median pVL 161
[range 74–262] copies/ml). The remaining five participants had
interrupted early cART before the scheduled TI date and had a
median pVL of 977 (range 95–100,000) copies/ml.
Twelve weeks after TI, 69/71 participants (97%) for whom a
pVL was available had a viral rebound. Following TI, the pVL
rebounded during the first 8 wk, with an estimated increase of
0.29 and 0.23 log10 copies/ml/wk in the 24- and 60-wk treatment
arms, respectively (p=0.05). From week 8 to 36 after randomi-
zation/TI the pVL did not change significantly in the no
treatment and 24-wk treatment arms, but increased by 0.01
log10 copies/ml/wk in the 60-wk treatment arm (p=0.02;
Figure 2A). The mean viral set point, 36 wk after randomiza-
tion/TI, was 4.8 (SD 0.6) log10 copies/ml in the no treatment arm,
and 4.0 (1.0) and 4.3 (0.9) log10 copies/ml in the 24- and 60-wk
treatment arms, respectively (comparing all three study arms,
p,0.001). Seven patients in the 24- and 60-wk treatment arms had
a pVL,1,000 copies/ml at viral set point, of whom four had a
pVL below 100 copies/ml, as compared to none in the no
treatment arm. From week 36 to 144 the pVL increased by 0.18
and 0.21 log10 copies/ml/y (p=0.9) in the 24- and 60-wk
treatment arms until the pVL in the three study arms slowly
converged 2–3 y after TI.
The mean CD4 cell count at TI in the 24- and 60-wk treatment
arms was 737 (SD 245) and 672 (245) cells/mm3, respectively
(p=0.3). After TI the CD4 cell counts showed an initial rapid
decline during the first 8 wk, with an estimated loss of 6.3 and 10.7
cells/mm3/wk in the 24- and 60-wk treatment arms, respectively
(p=0.3). From week 8 to 36 and week 36 to 144 after
randomization/TI, the CD4 count decline was similar between
all three study arms (p=0.9 and p=1.0 for both periods
respectively; Figure 2B). The mean CD4 count at viral set point
was 383 (SD 158) cells/mm3 in the no treatment arm, and 584
(202) and 503 (254) cells/mm3 in the 24- and 60-wk treatment
arms, respectively (comparing all three study arms, p,0.001).
Table 1. Baseline characteristics of 115 patients randomized over three study arms.
Characteristic Study Arm
No Treatment (n=36) 24 wk of cART (n=40) 60 wk of cART (n=39)
Age (years), mean (SD) 42 (11) 40 (10) 39 (9)
Male 36 (100) 36 (90) 38 (97)
MSM 31 (86) 31 (78) 34 (87)
Born in the Netherlands 33 (92) 33 (83) 32 (82)
Stage of PHI
Fiebig I–IV 27 (75) 27 (68) 30 (77)
Fiebig V–VI 9 (25) 13 (32) 9 (23)
Acute retroviral syndrome 30 (83) 31 (78) 34 (87)
CD4 cell count (cells/mm3), mean (SD) 458 (183) 584 (230) 483 (241)
Plasma HIV-1 RNA (log10 copies/ml), mean (SD) 5.1 (0.9) 5.1 (0.9) 4.9 (0.9)
Genotypic resistance mutationsa 1 (3) 5 (15) 3 (9)
Subtype B virusa 29 (91) 30 (91) 31 (91)
HLA B27 or B57b 1 (5) 1 (5) 1 (4)
CCR5 D32 heterozygosityc 1 (8) 3 (14) 5 (29)
CXCR4-using virusd 0 (0) 0 (0) 1 (6)
Interval between diagnosis and randomization (weeks), median (IQR) 4 (2–6) 4 (3–6) 4 (2–6)
Early cART nucleoside backbone
Zidovudine/lamivudine n.a. 19 (48) 22 (56)
Tenofovir/emtricitabine n.a. 21 (52) 17 (44)
Data are n (percent) unless indicated otherwise.
a16 patients with missing data.
b51 patients with missing data.
c65 patients with missing data.
d60 patients with missing data.
MSM, men who have sex with men; n.a., not applicable.
doi:10.1371/journal.pmed.1001196.t001
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Figure 2. Plasma viral load and CD4 cell count after randomization/treatment interruption in the no treatment and treatment arms.
Modeled mean pVL (A) and CD4 cell count (B) over time after randomization/TI in the no treatment and the 24- and 60-wk treatment arms for the
group of patients randomized over the three study arms. Graphs show the estimates (6 standard error of the mean) from the linear mixed models.
The box below each graph shows the number of pVL and CD4 cell count measurements at each time point used for fitting the linear mixed models.
c/ml, copies/ml.
doi:10.1371/journal.pmed.1001196.g002
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Total Time Off Therapy
At the time of analysis, 32/36 patients (89%) in the no treatment
arm had initiated cART, while 22/38 (58%) in the 24-wk
treatment arm and 24/38 (63%) in the 60-wk treatment arm had
restarted cART (p=0.008). 54/78 participants (69%) (re)started
cART according to the CD4 count criteria, four patients (5%)
because of severe symptoms/AIDS diagnosis, and 20 (26%)
patients because of a preference by physician or patient to restart
cART. Of note, 14 of these 20 patients had already had one CD4
count ,350 cells/mm3. The mean CD4 cell count at (re)start was
294 (SD 126) cells/mm3 in the no treatment arm, and 322 (114)
and 317 (127) cells/mm3 in the 24- and 60-wk treatment arms
(p=0.7). The median time off therapy after randomization/TI was
0.7 (95% confidence interval [CI] 0.0–1.8) y in the no treatment
arm, and 3.0 (1.9–4.2) and 1.8 (0.5–3.0) y in the 24- and 60-wk
treatment arms, respectively (log rank test comparing all three
study arms, p,0.001; Figure 3A). Using a CD4 cell count
threshold of 500 instead of 350 cells/mm3 for (re)start of cART,
34/36 (94%) patients in the no treatment arm, 26/38 (68%) in the
24-wk treatment arm, and 27/38 (71%) in the 60-wk treatment
arm would have (re)initiated cART (p=0.01). The median time off
therapy after randomization/TI would have been 0.5 (95% CI
0.4–0.6) y in the no treatment arm, and 2.0 (1.2–2.9) and 0.7 (0.3–
1.0) y in the 24- and 60-wk treatment arms, respectively (log rank
test, p=0.002).
Combining all treated patients (n=128), including those
participants who were randomized over the two treatment arms,
the median time off therapy was 3.1 (95% CI 2.1–4.0) and 2.1
(1.1–3.1) y in the patients treated for 24- and 60-wk, respectively
(p=0.03). However, 6/128 patients discontinued cART earlier
than planned, and 5/128 did not discontinue cART at the
scheduled TI date even though their CD4 cell counts were high
(range 480–863 cells/mm3; Figure 1). Excluding these 11 patients
in the per protocol analysis, the median time off therapy was 3.0
(95% CI 2.1–3.9) and 2.2 (1.1–3.3) y in the patients treated for 24-
and 60-wk, respectively (log rank test, p=0.1; Figure 3B).
Factors Associated with Time to (Re)Start of cART
We fitted six Cox regression models to compare the time to
(re)start of cART between the patients in the no treatment and 24-
and 60-wk treatment arms (Table 2). To account for potential bias,
including the differences in baseline CD4 cell count between the
three study arms, all Cox models were adjusted for differences
between groups in potential confounding factors by propensity
score weighting. In the adjusted Cox model for the mITT
population of the three-way randomized patients, the hazard ratio
for (re)start was significantly smaller for both treatment arms
compared to the no treatment arm (Model 1; Table 2). There were
no significant differences between the 24- and 60-wk treatment
arms (p=0.45). Repeating the analysis for the per protocol
population of the three-way randomized patients yielded similar
results (Model 2). Then we pooled the three-way and two-way
randomized patients and performed Cox analyses for both the
mITT population and the per protocol population, adjusting both
analyses for the randomization scheme of each patient. The
hazard ratio for time to (re)start of cART was significantly smaller
in both treatment arms as compared to the no treatment arm
(Models 3 and 4), and there were no significant differences
between the two treatment arms (p=0.77 and p=0.66, respec-
tively).
To explore the contribution of the lowering of the viral set point
and the increase in CD4 cell count during early treatment to the
timing of (re)start of cART, we added these two parameters to the
Cox models. Both the viral set point and the CD4 count at set
point were strong and independent predictors of time to (re)start of
cART in both the three-way randomized patients and the three-
and two-way randomized patients combined (Models 5 and 6). In
these two models, early cART was no longer significantly
associated with time to restart of cART, suggesting that the
lowering of the viral set point and the increase of the CD4 cell
count during the early treatment period explained for the most
part why early cART resulted in a clinical benefit.
In an attempt to identify further factors that predict a longer
time to restart of cART, we performed a final sub-group analysis
of all patients who had been treated with temporary early cART.
This model included both the viral set point and CD4 count at set
point. We found that the stage of PHI, the self-reported
occurrence of an acute retroviral syndrome, baseline pVL, and
all other investigated factors were not statistically significantly
associated with time to (re)start of cART.
Discussion
The present randomized trial provides the strongest evidence to
date of a clinical benefit of temporary cART initiated during PHI.
Early cART transiently lowered the viral set point by 0.5–0.8 log10
copies/ml, increased the CD4 cell count, and deferred the need
for initiation of cART during chronic HIV infection by 1.1–2.3 y.
Both viral set point and CD4 cell count measured at viral set point
were associated with time to (re)start of cART. The duration of
temporary early cART was not predictive, suggesting that 24 wk
of cART would be sufficient. The time off therapy was longer in
the 24-wk treatment arm than in the 60-wk treatment arm, but in
the per protocol analysis, and in the Cox models, which were
adjusted for possible confounders, there was no statistically
significant difference between the 24- and 60-wk treatment arms.
Overall, these findings are in agreement with the data of the
SETPOINT study and SPARTAC trial, in which, respectively, 36
and 48 wk of cART during early HIV infection modestly delayed
the need for subsequent initiation of cART [19,20].
An important strength of our study is that it showed a significant
benefit of temporary early cART as compared to deferred therapy
even using conservative mITT analyses, in which patients who
discontinued cART earlier than planned remained in the analyses
and those who did not discontinue cART at the scheduled TI date
were considered as having reached the study end point.
The study has several limitations. First, despite the random
allocation of patients to the different study arms, the mean baseline
CD4 cell count was by chance higher in the 24-wk treatment arm,
which might have affected the time to restart in this group.
However, the mean baseline CD4 cell count was not different
between the no treatment and 60-wk treatment arms, whereas the
time off therapy was significantly longer in the patients treated for
60 wk (p=0.02). More importantly, after adjusting for baseline
CD4 cell count in the Cox models, temporary early cART
remained associated with a longer time to subsequent reinitiation
of cART. Second, by providing the option of randomizing patients
over the two treatment arms only, we might have introduced
selection bias, as patients with more severe symptoms might have
been less likely to be enrolled in the three-way randomization.
However, we observed that the baseline characteristics, viral set
point, CD4 cell count measured at viral set point, and the time to
(re)start of cART did not differ between the three- and two-way
randomized treated patients. Additionally, the adjusted Cox
models also showed that the time to (re)start of cART was not
different for the treated patients randomized over three or two
study arms. Third, according to current treatment guidelines
zidovudine/lamivudine was replaced by tenofovir/emtricitabine
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halfway through the trial, which is a potential source of variability
in baseline characteristics between treatment groups. However,
the proportion of PHI patients treated with both drugs was
comparable in both treatment arms (Table 1).
The rate of HIV disease progression in our study was high: the
median time off therapy in the no treatment arm was less than 1 y.
More than 80% of patients presented with an acute retroviral
syndrome, which is a strong predictor of HIV disease progression
[30], suggesting that our results may not be generalizable to
asymptomatic seroconverters. Our findings are consistent with a
German cohort study in which 56 patients with untreated PHI had
a median time to CD4 cell count ,350 cells/mm3 of 8.3 mo after
seroconversion [31]. Data from the CASCADE cohort, a
collaboration of international cohorts of patients with a well-
estimated date of HIV seroconversion [32], demonstrated that in
179 untreated seroconverters the median time to initiation of
Figure 3. Probability of remaining off treatment in the no treatment and treatment arms. Kaplan-Meier curves of the probability of
remaining off treatment for the no treatment arm versus the 24- and 60-wk treatment arms in the patients randomized over the three study arms
using the mITT population (A), and for the 24- versus 60-wk treatment arms, including both treated patients randomized over all three study arms
and patients randomized over the two treatment arms, using the per protocol population (B).
doi:10.1371/journal.pmed.1001196.g003
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cART or reaching a CD4 cell count below 350 cells/mm3 was
approximately 1.5 y [6]. However, it was not reported whether
patients were symptomatic or not during the acute stage of the
disease.
The stage of PHI was not associated with time to (re)start of
cART. This is in contrast with findings from two previous cohort
studies. In one study, initiation of cART within 2 wk of antibody
seroconversion was associated with viral and immunological
benefits during at least 24 wk after TI as compared to starting
therapy between 2 wk and 6 mo after HIV seroconversion [3].
The second study reported that if early cART was initiated within
60 d after estimated HIV infection, it resulted in reduced pVL and
proviral HIV DNA levels as compared to later starters (between 61
and 120 d) or untreated controls for more than 1 y after TI [33].
The treated patients in our study had a median delay of 5 (IQR 3–
7) wk between the diagnosis of PHI and the start of early cART,
which means that the golden hour, in which the greatest benefits of
early cART could have been achieved, was possibly already
missed. Nevertheless, even with this delay we observed a clear
benefit of initiating cART during PHI.
Temporary cART initiated during PHI deferred the subsequent
restart of cART, which, according to the Cox models, was most
likely caused by the effects of the CD4 gain during treatment and
the transient lowering of the viral set point. The question remains
how the latter might be explained. We know that two critical
events in PHI are the massive destruction of CD4 T cells in the
gastrointestinal tract and the establishment of latent HIV
reservoirs. Early treatment may result in viral suppression and
immune restoration in gut-associated lymphoid tissue [34].
Alternatively, it may have an effect on the cellular HIV proviral
load and limit the size of the viral reservoirs [35,36]. Others have
postulated that early treatment enables virus-specific CD8+ T cells
to mature into fully differentiated effector cells, which might be
important in viral control [37]. Early treatment is also suggested to
help preserve specific anti-HIV responses [9,38], though we
previously found that HIV-specific CD4 T cell responses provided
no explanation for the lower viral set point in patients treated
during PHI [39]. Recently, we reported that HIV-1 dual infection
(coinfection or superinfection) was the main factor associated with
CD4 cell count decline in a cohort of 37 untreated men with
subtype B PHI [40]. A potential benefit of temporary early cART
may therefore be the prevention of early HIV-1 superinfection.
The gain in treatment-free years must be weighed against
potential disadvantages of starting cART in the acute stage of the
disease, a period in which patients are often physically and
emotionally distressed and adherence may be suboptimal. In
addition, early cART is often initiated before baseline resistance
test results are available and therefore may require ‘‘overtreat-
ment’’ to ensure an effective drug regimen, which may increase the
risk of drug toxicity. In our study, patients were started on a triple-
class therapy. In any case, if early treatment is considered, it
should at least include a boosted protease inhibitor until resistance
testing results are available [1]. Another concern may be the risk of
developing drug resistance after TI. Extended follow-up studies
will be needed to address this question.
Structured TI studies in chronic HIV infection have fallen into
disfavor after the SMART trial demonstrated that CD4-guided TI
was associated with adverse outcomes and a rapid CD4 cell count
decline as compared to continuous therapy [41]. The question is
whether this also holds true for patients who have initiated cART
shortly after seroconversion, before the development of severe
immunological dysfunction [42]. The ANRS PRIMO cohort
reported that a larger increase in CD4 cells during early cART
was associated with a markedly steeper decline after TI, and the
benefit of a limited course of cART was questioned [17]. In our
study, after an initial rapid, but limited CD4 cell decline during the
first 8 wk following TI in both the 24- and 60-wk treatment arms,
the slope of CD4 cell decline was comparable between all three
study arms.
Nonetheless, even in the patients in our study who received
temporary early cART, the total time off therapy was relatively
short. The lowering of the viral set point was transient, suggesting
Table 2. Propensity-score-weighted Cox proportional hazard models for time to (re)start of cART.
Characteristic Model
1 2 3 4 5 6
Patient population mITT Per Protocola mITT Per Protocola mITT mITT
Randomization scheme Three-way Three-way Three- and two-way Three- and two-way Three-way Three- and two-way
Number of patients 112 106 164 153 112 164
Fitted Cox model
24 wk cARTb 0.42 (0.25–0.73),
p= 0.002
0.43 (0.25–0.75),
p= 0.003
0.42 (0.24–0.74),
p= 0.003
0.41 (0.24–0.72),
p= 0.002
0.77 (0.41–1.42),
p=0.40
0.82 (0.46–1.47),
p=0.50
60 wk cARTb 0.55 (0.32–0.95),
p= 0.032
0.56 (0.32–0.99),
p= 0.047
0.45 (0.26–0.80),
p= 0.006
0.47 (0.26–0.84),
p= 0.011
0.78 (0.44–1.37),
p=0.38
0.56 (0.32–0.99),
p=0.045
Comparison of
24- and 60-wk cART
p= 0.45 p= 0.49 p= 0.77 p= 0.66 — —
CD4 cell count
at viral set pointc
— — — — 0.42 (0.32–0.53),
p,0.001
0.50 (0.41–0.60),
p,0.001
Viral set pointd — — — — 1.49 (1.01–2.22),
p=0.047
1.87 (1.33–2.63),
p,0.001
aPer protocol analysis excludes patients who discontinued cART earlier than planned and patients who did not interrupt cART but instead elected to continue cART for
reasons other than a low CD4 count or symptomatic disease.
bHazard ratio (95% CI) for early cART; the reference group is the no treatment arm.
cHazard ratio (95% CI) per 100 CD4 cells/mm3 increase.
dHazard ratio (95% CI) per 1 log10 copies/ml increase.
doi:10.1371/journal.pmed.1001196.t002
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loss of protective immune functions and the emergence of viral
escape mutants. Therefore, a reasonable question is whether early
cART should not be interrupted but continued for life, given the
concern that uncontrolled HIV replication and chronic immune
activation carry an increased risk of morbidity and mortality at all
stages of HIV infection [27]. Additionally, the continuation of
cART may have a public health benefit as it decreases
infectiousness [43–45].
In conclusion, this randomized study demonstrates a clear
clinical benefit of temporary cART initiated during PHI. Early
cART transiently lowered the viral set point and deferred the need
for restart of cART during chronic HIV infection. Although
extended follow-up studies are needed to evaluate the long-term
benefits of such early treatment, starting cART when the patient is
ready to do so seems the most reasonable advice for patients with
PHI.
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Editors’ Summary
Background. Every year, nearly three million people
become infected with HIV, the virus that causes AIDS. The
first stage of HIV infection—primary HIV infection—lasts a
few weeks and often goes undetected, although most
individuals develop a short, flu-like illness. During this stage
of infection, the immune system begins to make antibodies
to HIV. The second stage of HIV infection, which lasts many
years, also has no major symptoms but, during this stage,
HIV slowly destroys immune system cells, including CD4
cells, a type of lymphocyte. Eventually, the immune system is
unable to fight off other infections and patients enter the
third phase of HIV infection—symptomatic HIV infection. The
final stage—AIDS—is characterized by the occurrence of one
or more AIDS-defining conditions, which include severe but
unusual infections and several types of cancer. Early in the
AIDS epidemic, most HIV-positive people died within ten
years of infection. Nowadays, although there is still no cure
for HIV infection, HIV has become a chronic disease because
of the availability of combination antiretroviral therapy
(cART; cocktails of several powerful drugs). This means that
many HIV-positive people have a near-normal life span.
Why Was This Study Done? It is currently recommended
that people start cART when their CD4 count falls below 350
CD4 cells per cubic milliliter (cells/mm3) of blood, when they
develop severe constitutional symptoms such as fever
lasting longer than a month, or when they develop an
AIDS-defining condition. But could a short course of cART
during primary HIV infection be clinically beneficial? Some,
but not all, nonrandomized studies have shown that such
treatment reduces the viral set point (the stabilized viral load
that is reached after the immune system begins to make
antibodies to HIV; the viral load is the amount of virus in the
blood) and slows the decline of CD4 cell count in patients. In
this randomized trial (the Primo-SHM trial), the researchers
assess the clinical benefit of temporary cART initiated during
primary HIV infection by measuring its effects on the viral set
point and on when patients have to restart cART during
chronic HIV infection. In a randomized controlled trial,
patients are assigned by the play of chance to receive
different treatments and then followed to compare the
effects of these treatments.
What Did the Researchers Do and Find? The researchers
assigned 168 patients with primary HIV infection to receive
no treatment, 24 weeks of cART, or 60 weeks of cART. They
measured the viral set point (the viral load in the blood 36
weeks after randomization in the no treatment arm and 36
weeks after cART interruption in the treatment arms) and
determined the time off therapy (the time between
randomization and the start of cART in the no treatment
arm, and the time between treatment interruption and
restart of cART in the treatment arms) for each patient. cART
was (re)started following two consecutive CD4 counts below
350 cells/mm3 or when symptomatic HIV disease developed.
The average viral set point was lower in the patients who
received early cART than in those who had no treatment.
Moreover, on average, the patients in the no treatment arm
started cART 0.7 years after randomization whereas those in
the 24- and 60-week treatment arms restarted cART after 3.0
and 1.8 years, respectively. There was no statistically
significant difference between the 24-week and 60-week
treatment arms in time off therapy.
What Do These Findings Mean? These findings suggest
that temporary cART during primary HIV infection can
transiently lower the viral set point and can delay the need
to restart cART during chromic HIV infection. They also
suggest that 24 weeks of cART during primary HIV is as
effective as 60 weeks of treatment. These findings need to be
confirmed in other settings, and follow-up studies are
needed to evaluate the long-term benefits of early
temporary cART, but given the short time between cART
interruption and treatment restart, the researchers suggest
that not interrupting early cART, but instead continuing it for
life, should be considered. However, they add, because
patients are often physically and emotionally distressed at
this stage of HIV infection, adherence to cART during primary
HIV infection may be suboptimal, and so patients with
primary HIV infection should be advised to start cART only
when they feel ready to start treatment.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001196.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS,
including information on the clinical progression of HIV
infection
N NAM/aidsmap provides information about HIV/AIDS, in-
cluding a factsheet on primary infection
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including detailed
information on HIV treatment and care and on the stages
of HIV infection (in English and Spanish)
N The World Health Organization’s 2010 antiretroviral
therapy guidelines provide recommendations on when
to initiate cART
N Information about Primo-SHM is available
N Patient stories about livingwith HIV/AIDS are available through
Avert and through the charity website Healthtalkonline
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